Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 61.90% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -22.14% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 0.46% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 125.00% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 425.00% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -267.74% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 16.33% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -18.09% |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 272.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.00% |
| Dec 31, 2025 | 60.16% |
| Sep 30, 2025 | 43.99% |
| Jun 30, 2025 | 57.89% |
| Mar 31, 2025 | -50.27% |
| Dec 31, 2024 | 96.36% |
| Sep 30, 2024 | -25.47% |
| Jun 30, 2024 | -64.03% |
| Mar 31, 2024 | 204.07% |
| Dec 31, 2023 | -13.64% |
| Sep 30, 2023 | 114.57% |
| Jun 30, 2023 | 30.05% |
| Mar 31, 2023 | -209.14% |
| Dec 31, 2022 | 3,304.76% |
| Sep 30, 2022 | 59.87% |
| Jun 30, 2022 | 33.82% |
| Mar 31, 2022 | -146.39% |
| Dec 31, 2021 | -95.56% |
| Sep 30, 2021 | 402.94% |
| Jun 30, 2021 | -13.20% |